Effect of GLP-1 Receptor Agonists on Waist Circumference Among Type 2 Diabetes Patients: a Systematic Review and Network Meta-analysis

Overview

Journal Endocrine

Specialty Endocrinology

Date 2014 Aug 14

PMID 25115635

Citations 16

Authors

Feng Sun

Shanshan Wu

Shuxia Guo

Kai Yu

Zhirong Yang

Lishi Li

Yuan Zhang

Linong Ji

Siyan Zhan

Affiliations

Soon will be listed here.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with type 2 diabetes. However, the effect on abdominal obesity has not yet been confirmed. The study aimed to systematically evaluate the effect of GLP-1RAs on waist circumference in patients with type 2 diabetes. MEDLINE, EMBASE, the Cochrane library and www.clinicaltrialgov were searched through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional anti-diabetic drugs with a duration≥8 weeks. Weighted mean difference was estimated using random-effect model. Network meta-analysis was performed to supplement direct comparisons. Seventeen trials with 12 treatments were included. Overall, significant reductions on waist circumference following treatment of liraglutide--1.8 mg once daily (-5.24 cm, 95% CI -7.68, -2.93), liraglutide--1.2 mg once daily (-4.73 cm, 95% CI -6.68, -2.65) and exenatide--10 μg twice daily (-1.34 cm, 95 % CI -2.00, -0.75) were detected versus placebo. The reduction effect was more evident when compared with insulin and thiazolidinediones (range -1.71 to -8.03 cm). Compared with exenatide, liraglutide--0.6 mg once daily, taspoglutide, liraglutide--1.2 mg once daily and liraglutide--1.8 mg once daily significantly decreased waist circumference from -3.32 to -6.01 cm. Besides, liraglutide--1.8 mg once daily significantly decreased waist circumference by -1.73 cm (95 % CI -3.04, -0.55) versus sitagliptin, whereas no significant difference following liraglutide--1.2-mg-once-daily treatment was detected compared with liraglutide--1.8 mg once daily and sitagliptin. Reduction was observed with statistical significance for exenatide--10 μg twice daily compared with exenatide--5 μg twice daily (-1.21 cm, 95% CI -2.43, -0.06). Ranking probability analysis indicated liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily decreased waist circumference most among all 12 treatments with probability of 98.36% and 91.82%, respectively. Some GLP-1RAs, especially liraglutide--1.8 mg once daily and liraglutide--1.2 mg once daily, were associated with a significant reduction in waist circumference.

Citing Articles

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.

Hamed K, Alosaimi M, Ali B, Alghamdi A, Alkhashi T, Alkhaldi S Cureus. 2024; 16(9):e68390.

PMID: 39355484 PMC: 11444311. DOI: 10.7759/cureus.68390.

Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.

Liu L, Shi H, Shi Y, Wang A, Guo N, Tao H Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065679 PMC: 11279917. DOI: 10.3390/ph17070828.

Efficacy and Safety of a Biosimilar Liraglutide (Melitide) Versus the Reference Liraglutide (Victoza) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial.

Esteghamati A, Zamanzadeh M, Malek M, Khaledi M, Monavari A, Najafi L Diabetes Ther. 2023; 14(11):1889-1902.

PMID: 37707701 PMC: 10570258. DOI: 10.1007/s13300-023-01462-w.

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.

Rentzeperi E, Pegiou S, Koufakis T, Grammatiki M, Kotsa K J Pers Med. 2022; 12(3).

PMID: 35330453 PMC: 8950819. DOI: 10.3390/jpm12030454.

Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists.

Tommerdahl K, Nadeau K, Bjornstad P Adv Chronic Kidney Dis. 2021; 28(4):337-346.

PMID: 34922690 PMC: 9119551. DOI: 10.1053/j.ackd.2021.06.001.

References

Bhushan R, Elkind-Hirsch K, Bhushan M, Butler W, Duncan K, Marrioneaux O . Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol Ther. 2009; 11(6):353-9. DOI: 10.1089/dia.2008.0090. View

Brunton S . GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?. Int J Clin Pract. 2014; 68(5):557-67. PMC: 4238422. DOI: 10.1111/ijcp.12361. View

Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman M . Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks. J Diabetes Investig. 2014; 2(3):210-7. PMC: 4014921. DOI: 10.1111/j.2040-1124.2010.00084.x. View

van Bloemendaal L, Ten Kulve J, la Fleur S, IJzerman R, Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2013; 221(1):T1-16. DOI: 10.1530/JOE-13-0414. View

Bunck M, Diamant M, Eliasson B, Corner A, Shaginian R, Heine R . Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010; 33(8):1734-7. PMC: 2909051. DOI: 10.2337/dc09-2361. View

Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S . One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label.... Int J Clin Pract. 2011; 65(4):397-407. PMC: 3085127. DOI: 10.1111/j.1742-1241.2011.02656.x. View

DeFronzo R, Triplitt C, Qu Y, Lewis M, Maggs D, Glass L . Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010; 33(5):951-7. PMC: 2858197. DOI: 10.2337/dc09-1521. View

Henry R, Mudaliar S, Kanitra L, Woloschak M, Balena R . Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial. J Clin Endocrinol Metab. 2012; 97(7):2370-9. DOI: 10.1210/jc.2011-3253. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

10.

Hollander P, Lasko B, Barnett A, Bengus M, Kanitra L, Pi-Sunyer F . Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study). Obesity (Silver Spring). 2013; 21(2):238-47. DOI: 10.1002/oby.20042. View

11.

Wilson P, DAgostino R, Parise H, Sullivan L, Meigs J . Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112(20):3066-72. DOI: 10.1161/CIRCULATIONAHA.105.539528. View

12.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

13.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

14.

Lorber D . GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther. 2013; 31(4):238-49. DOI: 10.1111/1755-5922.12000. View

15.

Ezenwaka C, Okoye O, Esonwune C, Onuoha P, Dioka C, Osuji C . High prevalence of abdominal obesity increases the risk of the metabolic syndrome in Nigerian type 2 diabetes patients: using the International Diabetes Federation worldwide definition. Metab Syndr Relat Disord. 2014; 12(5):277-82. DOI: 10.1089/met.2013.0139. View

16.

Goykhman S, Drincic A, Desmangles J, Rendell M . Insulin Glargine: a review 8 years after its introduction. Expert Opin Pharmacother. 2009; 10(4):705-18. DOI: 10.1517/14656560902775677. View

17.

Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D . A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab. 2010; 12(12):1058-65. DOI: 10.1111/j.1463-1326.2010.01251.x. View

18.

Li Y, Perry T, Kindy M, Harvey B, Tweedie D, Holloway H . GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A. 2009; 106(4):1285-90. PMC: 2633544. DOI: 10.1073/pnas.0806720106. View

19.

Diamant M, Van Gaal L, Stranks S, Guerci B, MacConell L, Haber H . Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012; 35(4):683-9. PMC: 3308312. DOI: 10.2337/dc11-1233. View

20.

Song F, Altman D, Glenny A, Deeks J . Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003; 326(7387):472. PMC: 150178. DOI: 10.1136/bmj.326.7387.472. View